{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:40Z","timestamp":1793970880179,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan\u2019s Agency for Medical Research and Development, AMED","award":["18lk0201055h0003"],"award-info":[{"award-number":["18lk0201055h0003"]}]},{"name":"Japan\u2019s Agency for Medical Research and Development, AMED","award":["18ek0109277h0002"],"award-info":[{"award-number":["18ek0109277h0002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1118-1","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T10:47:14Z","timestamp":1560422834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9347-4448","authenticated-orcid":false,"given":"Michio","family":"Ozeki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Yasue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Fukao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"1118_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.sempedsurg.2014.07.006","volume":"23","author":"CC Trenor 3rd","year":"2014","unstructured":"Trenor CC 3rd, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg. 2014;23:186\u201390.","journal-title":"Semin Pediatr Surg"},{"key":"1118_CR2","unstructured":"International Society for the Study of Vascular Anomalies: ISSVA classification for Vascular Anomalies (approved at the May 2018 General Assembly in Amsterdam, the Netherlands) \n                    http:\/\/issva.org\/classification\n                    \n                   (Accessed June 2018)."},{"key":"1118_CR3","first-page":"227","volume":"62","author":"LS Foley","year":"2015","unstructured":"Foley LS, Kulungowski AM. Vascular anomalies in pediatrics. Adv Pediatr Infect Dis. 2015;62:227\u201355.","journal-title":"Adv Pediatr Infect Dis"},{"key":"1118_CR4","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/pbc.25914","volume":"63","author":"M Ozeki","year":"2016","unstructured":"Ozeki M, Fujino A, Matsuoka K, Nosaka S, Kuroda T, Fukao T. Clinical features and prognosis of generalized lymphatic anomaly, Kaposiform lymphangiomatosis and Gorham-stout disease. Pediatr Blood Cancer. 2016;63:832\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"1118_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pbc.23124","volume":"57","author":"AM Hammill","year":"2011","unstructured":"Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57:1018\u201324.","journal-title":"Pediatr Blood Cancer"},{"key":"1118_CR6","doi-asserted-by":"publisher","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","volume":"2","author":"DM Adams","year":"2016","unstructured":"Adams DM, Trenor CC 3rd, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;2:e20153257.","journal-title":"Pediatrics"},{"key":"1118_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10456-014-9453-2","volume":"18","author":"E Boscolo","year":"2015","unstructured":"Boscolo E, Coma S, Luks VL, et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis. 2015;18:151\u201362.","journal-title":"Angiogenesis"},{"key":"1118_CR8","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1002\/dvdy.22328","volume":"239","author":"MV Flores","year":"2010","unstructured":"Flores MV, Hall CJ, Crosier KE, Crosier PS. Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies. Dev Dyn. 2010;239:2128\u201335.","journal-title":"Dev Dyn"},{"key":"1118_CR9","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.ki.5002112","volume":"71","author":"S Huber","year":"2007","unstructured":"Huber S, Bruns CJ, Schmid G, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71:771\u20137.","journal-title":"Kidney Int"},{"key":"1118_CR10","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1349-7006.2007.00439.x","volume":"98","author":"S Kobayashi","year":"2007","unstructured":"Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007;98:726\u201333.","journal-title":"Cancer Sci"},{"key":"1118_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1593\/neo.111570","volume":"14","author":"Y Luo","year":"2012","unstructured":"Luo Y, Liu L, Rogers D, et al. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia. 2012;14:228\u201337.","journal-title":"Neoplasia"},{"key":"1118_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1097\/00005650-200108000-00006","volume":"39","author":"JW Varni","year":"2001","unstructured":"Varni JW, Seid M, Kurtin P. PedsQL\u2122 4.0: reliability and validity of the pediatric quality of life inventory\u2122 version 4.0 generic Core scales in healthy and patient populations. Med Care. 2001;39:800\u201312.","journal-title":"Med Care"},{"key":"1118_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/BF00433916","volume":"5","author":"DL Fairclough","year":"1996","unstructured":"Fairclough DL, Cella DF. Functional assessment of Cancer therapy (FACT-G): non-response to individual questions. Qual Life Res. 1996;5:321\u20139.","journal-title":"Qual Life Res"},{"key":"1118_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1185\/03007995.2011.644849","volume":"28","author":"PF Fogarty","year":"2012","unstructured":"Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. Selective validation of the WHO bleeding scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012;28:79\u201387.","journal-title":"Curr Med Res Opin"},{"key":"1118_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604\u20137.","journal-title":"Stroke"},{"key":"1118_CR16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00431-015-2572-y","volume":"174","author":"H Lackner","year":"2015","unstructured":"Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015;174:1579\u201384.","journal-title":"Eur J Pediatr"},{"key":"1118_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1089\/lrb.2017.0062","volume":"16","author":"S Wiegand","year":"2018","unstructured":"Wiegand S, Wichmann G, Dietz A. Treatment of lymphatic malformations with the mTOR inhibitor Sirolimus: a systematic review. Lymphat Res Biol. 2018;16:330\u20139.","journal-title":"Lymphat Res Biol"},{"key":"1118_CR18","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1172\/JCI71614","volume":"124","author":"P Brouillard","year":"2014","unstructured":"Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest. 2014;124:898\u2013904.","journal-title":"J Clin Invest"},{"key":"1118_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.otc.2017.09.006","volume":"51","author":"A Queisser","year":"2018","unstructured":"Queisser A, Boon LM, Vikkula M. Etiology and genetics of congenital vascular lesions. Otolaryngol Clin N Am. 2018;51:41\u201353.","journal-title":"Otolaryngol Clin N Am"},{"key":"1118_CR20","doi-asserted-by":"publisher","first-page":"e90103","DOI":"10.1172\/jci.insight.90103","volume":"2","author":"P Baluk","year":"2017","unstructured":"Baluk P, Yao LC, Flores JC, Choi D, Hong YK, McDonald DM. Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight. 2017;2:e90103.","journal-title":"JCI Insight"},{"key":"1118_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.2340\/00015555-2300","volume":"96","author":"M Nadal","year":"2016","unstructured":"Nadal M, Giraudeau B, Tavernier E, et al. Efficacy and safety of mammalian target of rapamycin inhibitors in vascular anomalies: a systematic review. Acta Derm Venereol. 2016;96:448\u201352.","journal-title":"Acta Derm Venereol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1118-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1118-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T19:34:58Z","timestamp":1591904098000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1118-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1118"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1118-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"4 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received approval from the Institutional Review Board at Gifu University Hospital, Gifu, Japan. Each patient or patient\u2019s parent signed an informed consent after receiving a summary explaining study procedures. The trial was also registered in the UMIN Clinical Trials Registry (UMIN000016580).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each patient or patient\u2019s parent signed a consent for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.O. and T.F. received research funding from Nobelpharma. Sirolimus tablets were supplied by Nobelpharma. The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}